Mutsva Mushonga Wekushandisa Kurapwa kweAdvanced Solid Tumors

rakanyorwa mupepeti

Nuvation Bio Inc. nhasi yazivisa kuti US Food and Drug Administration (FDA) yakabvisa chirongwa chayo chekuongorora mushonga mutsva (IND) kuongorora NUV-868, BD2-selective oral small molecule bromodomain uye extra-terminal (BET) inhibitor, ye kurapwa kwemamota akasimba, anosanganisira gomarara reovarian, cancer cancer, metastatic castration resistant cancer yeprostate (mCRPC), uye kenza yemazamu katatu isina kunaka (TNBC).

Print Friendly, PDF & Email

"Kubvumidzwa kweIND yedu yekushandisa yeNUV-868 chiitiko chakakosha kuNuvation Bio sezvo ichiratidzira yechina IND mumwedzi gumi nemina yapfuura papiipi yedu yakadzika yekurapa cancer inonangana nemhando dzakawanda dzemamota," akadaro David Hung, MD, muvambi. , mutungamiri, uye mukuru mukuru weNuvation Bio. "Tinokurudzirwa nekusarudzika uye nekugona kuvandudzwa kushivirira kwakaratidzwa neNUV-14 muzvidzidzo zvepamberi, uye tinotarisira kufambisira mberi chirongwa ichi muChikamu chekutanga pakati pegore ra868."

NUV-868 inhibits BRD4, iyo inhengo yakakosha yemhuri yeBET iyo epigenetically inodzora mapuroteni anodzora bundu kukura uye kusiyanisa. NUV-868 yakagadzirirwa kuve yakanyanya kusarudzira BD2 pane BD1 mukuyedza kudzivirira kurapwa kunodzikamisa chepfu yeimwe BRD4 inhibitors senge gastrointestinal (GI) uye bone marrow toxicity. Zvidzidzo zvepreclinical zvakaratidza kuti NUV-868 ingangoita ka1,500 kusarudzwa kweBD2 pane BD1. Asina-selective BD1/2 inhibitors mukusimudzira akabatanidzwa nenyaya dzekushivirira, pamwe nekuda kwekunyanya BD1 inhibition.

Nekucheneswa kweiyi IND yeNUV-868 mumamota akasimba akasimba, Nuvation Bio ichave ichitanga Chidzidzo cheChikamu 1/2 cheNUV-868 semonotherapy uye pamwe chete neolaparib kana enzalutamide mumhando dzakawanda dzebundu. Iyi protocol (NUV-868-01) ichatanga nePhase 1 monotherapy dose escalation kudzidza mune advanced solid solid tumor varwere. Chidzidzo chePhase 1b chinobva chatangwa kuongorora NUV-868 pamwe chete neolaparib mune yakamborapwa gomarara reovarian, pancreatic cancer, mCRPC, uye TNBC varwere uye pamwe chete ne enzalutamide yemCRPC varwere inoteverwa nePhase 2b kudzidza kuti uenderere mberi nekuongorora kuchengetedzwa uye kushanda zvakanaka. kamwechete iyo yakakurudzirwa Phase 2 musanganiswa dose yakatemwa. A Phase 2 monotherapy chidzidzo chinozotangwa zvakare mumCRPC varwere zvakare kuti vaenderere mberi nekuongorora kuchengetedzeka uye kushanda.

Print Friendly, PDF & Email

Nezvomunyori

mupepeti

Mupepeti mukuru we eTurboNew ndiLinda Hohnholz. Iye anogara muTN HQ muHonolulu, Hawaii.

Leave a Comment